stockrow
Monday 2 November 2026
Export TWST’s income statement to Excel — free account
Twist Bioscience Corporation
TWST Healthcare Biotechnology
Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.
- Revenue
- +23.2%
- EPS
- −264.7%
- Free cash flow
- −7.23%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
129.86
22.92
−15.00%
Follow TWST
Alert me
Twist Bioscience Corporation (TWST) P/E ratio
Twist Bioscience Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 31 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TWST Twist Bioscience Corporation | n/m |
| MDGL Madrigal Pharmaceuticals, Inc. compare | n/m |
| KYMR Kymera Therapeutics, Inc. compare | n/m |
| PCVX Vaxcyte, Inc. compare | n/m |
| SMMT Summit Therapeutics PLC compare | n/m |
| JAZZ Jazz Pharmaceuticals PLC compare | 14.2× |
| TECH Bio-Techne Corp compare | 62.1× |
| CAI Caris Life Sciences,�Inc. compare | 91.3× |
| BMRN BioMarin Pharmaceutical Inc. compare | 154× |
| Biotechnology industry median | 12.4× |
| Healthcare sector median | 25.8× |
| Market median | 18.6× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)